Lazard Asset Management
CGEM icon

Lazard Asset Management’s Cullinan Oncology CGEM Stock Holding History

Lazard Asset Management’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,273
Closed -$58K – 2163
2021
Q2 		$58K Buy
+2,273
New +$69.9K ﹤0.01% 1536

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Lazard Asset Management's CGEM Position: Q3 2021 in Review

Lazard Asset Management sold out of Cullinan Oncology (CGEM) in Q3 2021, closing a stake of 2,273 shares — an estimated $58K sold.

Lazard Asset Management first reported a position in CGEM in Q2 2021 and held it in 1 quarter. The position peaked at $58K in Q2 2021. 66 funds tracked by Wall St. Rank hold CGEM as of Q3 2021.

  • Lazard Asset Management reported no remaining Cullinan Oncology position as of Q3 2021 after selling out during the quarter.
  • Lazard Asset Management sold 2,273 Cullinan Oncology shares in Q3 2021, an estimated $58K.
  • Lazard Asset Management first reported a position in Cullinan Oncology in Q2 2021 and held it in 1 quarter.
  • Lazard Asset Management's Cullinan Oncology position peaked at $58K in Q2 2021.
  • 66 funds tracked by Wall St. Rank held Cullinan Oncology as of Q3 2021.

Based on Lazard Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.